Amferia, a Swedish medtech leveraging antimicrobial peptides (AMPs) derived from the mammalian immune system to combat infections, believes its technology will reinforce the health care system’s “arsenal against bacteria.”
Globally, there are 4.95 million deaths associated with antimicrobial resistance (AMR) each year, and experts predict the figure could rise to 10 million by 2050. The crisis threatens modern medicine, given that surgery, chemotherapy and other procedures rely on antimicrobials to avoid infection
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?